Advertisement

Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease

  • Christopher M. Johnson
  • Themistocles Dassopoulos
Inflammatory Bowel Disease (S Hanauer, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Inflammatory Bowel Disease

Abstract

Purpose of Review

The increased use of biologic agents over the past two decades has led to a reappraisal of the role of the immunomodulators (thiopurines and methotrexate) in the treatment of inflammatory bowel disease. The purpose of this review is to summarize recent data on the use of thiopurines and methotrexate either as monotherapy or as part of combination therapy with biologic agents.

Recent Findings

Recent studies have addressed the need for concomitant immunomodulatory therapy in treatment-naïve patients starting anti-TNF-α therapy, the appropriate dose of the immunomodulator in this setting, the minimum duration of combination therapy, and the possible mechanisms by which immunomodulators enhance the effectiveness of anti-TNF-α agents. Little is known about the role of immunomodulators in combination with agents belonging to other classes of biologic therapies. Recent studies have shown that methotrexate is not effective in inducing or maintaining remission in ulcerative colitis. Finally, several studies have broadened our understanding of the infection and malignancy risks of the immunomodulators.

Summary

Immunomodulators continue to have a place in the treatment of inflammatory bowel disease. However, with the ever-increasing list of biologic agents, properly positioning the immunomodulators within the overall therapeutic scheme is a complicated task. In order to optimize outcomes, each patient requires an individualized approach, which takes into account risks, benefits, cost, alternatives, and patient preferences.

Keywords

Immunomodulator Thiopurines Methotrexate Crohn’s disease Ulcerative colitis Inflammatory bowel disease 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn’s disease. Lancet. 1971;2(7731):944–7.CrossRefGoogle Scholar
  2. 2.
    Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn’s disease. Am J Dig Dis. 1975;20(8):721–6.CrossRefGoogle Scholar
  3. 3.
    Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302(18):981–7.CrossRefGoogle Scholar
  4. 4.
    Feagan BG, Rochon J, Fedorak RN, et al; for the North American Crohn’s Study Group Investigators. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med 1995;332(5):292–7.Google Scholar
  5. 5.
    Colombel JF, Sandborn WJ, Reinisch W, et al; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 2010;362(15):1383–95.Google Scholar
  6. 6.
    Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400. e3CrossRefGoogle Scholar
  7. 7.
    Matsumoto T, Motoya S, Watanabe K, et al; DIAMOND study group. Adalimumab monotherapy and a combination with azathioprine for Crohn’s disease: a prospective, randomized trial. J Crohns Colitis 2016;10(11):1259–66.Google Scholar
  8. 8.
    Thomas SS, Borazan N, Barroso N, Duan L, Taroumian S, Kretzmann B, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs. 2015;29(4):241–58.CrossRefGoogle Scholar
  9. 9.
    Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111(8):1133–45.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Ben-Horin S, Goldstein I, Fudim E, Picard O, Yerushalmi Z, Barshack I, et al. Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines. Gut. 2009;58(3):396–403.CrossRefGoogle Scholar
  11. 11.
    Atreya I, Diall A, Dvorsky R, Atreya R, Henninger C, Grün M, et al. Designer thiopurine-analogues for optimised immunosuppression in inflammatory bowel diseases. J Crohns Colitis. 2016;10(10):1132–43.CrossRefGoogle Scholar
  12. 12.
    Colombel JF, Adedokun OJ, Gasink C, et al. Higher levels of infliximab may alleviate the need of azathioprine comedication in the treatment of patients with Crohn’s disease: a SONIC post-hoc analysis [AGA abstract 134]. Gastroenterology. 2017;152(5)(suppl 1): S37–8.Google Scholar
  13. 13.
    • Bouguen G, Sninsky C, Tang KL, et al. Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC. Inflamm Bowel Dis. 2015;21(3):606-14. Data supporting the concept that AZA increases IFX concentrations but also has an independent anti-inflammatory effect in patients with CD. Google Scholar
  14. 14.
    Yarur AJ, Kubiliun MJ, Czul F, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol. 2015;13(6):1118–24. e3CrossRefGoogle Scholar
  15. 15.
    Roblin X, Boschetti G, Williet N, Nancey S, Marotte H, Berger A, et al. Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial. Aliment Pharmacol Ther. 2017;46(2):142–9.CrossRefGoogle Scholar
  16. 16.
    Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134(7):1861–8.CrossRefGoogle Scholar
  17. 17.
    Grossi V, Lerer T, Griffiths A, LeLeiko N, Cabrera J, Otley A, et al. Concomitant use of immunomodulators affects the durability of infliximab therapy in children with Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(10):1748–56.CrossRefGoogle Scholar
  18. 18.
    Kierkuś J, Iwańczak B, Wegner A, Dadalski M, Grzybowska-Chlebowczyk U, Łazowska I, et al. Monotherapy with infliximab versus combination therapy in the maintenance of clinical remission in children with moderate to severe Crohn disease. J Pediatr Gastroenterol Nutr. 2015;60(5):580–5.CrossRefGoogle Scholar
  19. 19.
    Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369(8):699–710.Google Scholar
  20. 20.
    Sandborn WJ, Feagan BG, Rutgeerts P, et al; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013;369(8):711–21.Google Scholar
  21. 21.
    Colombel JF, Loftus EV, Siegel CA, et al. Efficacy of vedolizumab with concomitant corticosteroid or immunomodulator use in patients with ulcerative colitis from GEMINI 1 [AGA abstract Sa1271]. Gastroenterology. 2015;148(4)(suppl 1);S277–8.Google Scholar
  22. 22.
    Eriksson C, Marsal J, Bergemalm D, Vigren L, Björk J, Eberhardson M, et al. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for inflammatory bowel disease (SWIBREG). Scand J Gastroenterol. 2017;52(6–7):722–9.CrossRefGoogle Scholar
  23. 23.
    Amiot A, Grimaud JC, Peyrin-Biroulet L, et al. Observatory on Efficacy and of Vedolizumab in Patients With Inflammatory Bowel Disease Study Group; Groupe d’Etude Therapeutique des Affections Inflammatoires du tube Digestif. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14(11):1593–601. e2CrossRefGoogle Scholar
  24. 24.
    Shelton E, Allegretti JR, Stevens B, Lucci M, Khalili H, Nguyen DD, et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm Bowel Dis. 2015;21(12):2879–85.CrossRefPubMedCentralGoogle Scholar
  25. 25.
    Stallmach A, Langbein C, Atreya R, Bruns T, Dignass A, Ende K, et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease—a prospective multicenter observational study. Aliment Pharmacol Ther. 2016;44(11–12):1199–212.CrossRefGoogle Scholar
  26. 26.
    Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111(8):1147–55.CrossRefGoogle Scholar
  27. 27.
    Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66(5):839–51.CrossRefGoogle Scholar
  28. 28.
    Feagan BG, Sandborn WJ, Gasink C, et al; UNITI–IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2016;375(20):1946–60.Google Scholar
  29. 29.
    Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, et al. Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn’s disease [published online ahead of print February 3, 2018]. Gastroenterology. 2018;154(6):1660–71.CrossRefGoogle Scholar
  30. 30.
    Beaugerie L, Brousse N, Bouvier AM, et al; CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374(9701):1617–25.Google Scholar
  31. 31.
    •• Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318(17):1679–86. Study of the French National Health Insurance claim database that found that both anti-TNFα agents and thiopurines were associated with an increased risk of lymphoma. CrossRefPubMedCentralGoogle Scholar
  32. 32.
    Jones JL, Kaplan GG, Peyrin-Biroulet L, et al. Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn’s disease: a meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2015;13(13):2233–40.e1–2;quiz e177–8.Google Scholar
  33. 33.
    Osterman MT, Haynes K, Delzell E, et al. Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(7):1293–301. e5;quiz e70,e72CrossRefPubMedCentralGoogle Scholar
  34. 34.
    Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, et al. Crohn’s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab. Am J Gastroenterol. 2016;111(12):1806–15.CrossRefGoogle Scholar
  35. 35.
    Sepulveda FE, de Saint Basile G. Hemophagocytic syndrome: primary forms and predisposing conditions. Curr Opin Immunol. 2017;49:20–6.CrossRefGoogle Scholar
  36. 36.
    Henter JI, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.CrossRefGoogle Scholar
  37. 37.
    Posthuma EF, Westendorp RG, van der Sluys VA, Kluin-Nelemans JC, Kluin PM, Lamers CB. Fatal infectious mononucleosis: a severe complication in the treatment of Crohn’s disease with azathioprine. Gut. 1995;36(2):311–3.CrossRefPubMedCentralGoogle Scholar
  38. 38.
    Garrido Serrano A, Pérez Martín F, Guerrero Igea FJ, Galbarro Muñoz J, Palomo GS. Fatal infectious mononucleosis during azathioprine treatment in Crohn’s disease [in Spanish]. Gastroenterol Hepatol. 2000;23(1):7–8.PubMedGoogle Scholar
  39. 39.
    N’guyen Y, Andreoletti L, Patey M, et al. Fatal Epstein-Barr virus primo infection in a 25-year-old man treated with azathioprine for Crohn’s disease. J Clin Microbiol. 2009;47(4):1252–4.CrossRefPubMedCentralGoogle Scholar
  40. 40.
    Biank VF, Sheth MK, Talano J, Margolis D, Simpson P, Kugathasan S, et al. Association of Crohn’s disease, thiopurines, and primary Epstein-Barr virus infection with hemophagocytic lymphohistiocytosis. J Pediatr. 2011;159(5):808–12.CrossRefPubMedCentralGoogle Scholar
  41. 41.
    Sijpkens YW, Allaart CF, Thompson J, et al. Fever and progressive pancytopenia in a 20-year-old woman with Crohn’s disease. Ann Hematol. 1996;72(4):286–90.CrossRefGoogle Scholar
  42. 42.
    Babu TG, Boctor D, Davey A, Bond MC, Jacobson K. Cytomegalovirus-associated hemophagocytic syndrome in a child with Crohn disease receiving azathioprine. J Pediatr Gastroenterol Nutr. 2004;39(4):418–21.CrossRefGoogle Scholar
  43. 43.
    van Langenberg DR, Morrison G, Foley A, Buttigieg RJ, Gibson PR. Cytomegalovirus disease, haemophagocytic syndrome, immunosuppression in patients with IBD: “a cocktail best avoided, not stirred.”. J Crohns Colitis. 2011;5(5):469–72.CrossRefGoogle Scholar
  44. 44.
    N’Guyen Y, Baumard S, Salmon JH, et al. Cytomegalovirus associated hemophagocytic lymphohistiocytosis in patients suffering from Crohn’s disease treated by azathioprine: a series of four cases. Inflamm Bowel Dis. 2011;17(9):E116–8.CrossRefGoogle Scholar
  45. 45.
    Fitzgerald MP, Armstrong L, Hague R, Russell RK. A case of EBV driven haemophagocytic lymphohistiocytosis complicating a teenage Crohn’s disease patient on azathioprine, successfully treated with rituximab. J Crohns Colitis. 2013;7(4):314–7.CrossRefGoogle Scholar
  46. 46.
    Mikolajczyk AE, Rubin DT, McConville JF. A diagnosis that eats at you. Gastroenterology. 2013;145(2):289–489.CrossRefGoogle Scholar
  47. 47.
    Kohara MM, Blum RN. Cytomegalovirus ileitis and hemophagocytic syndrome associated with use of anti-tumor necrosis factor-alpha antibody. Clin Infect Dis. 2006;42(5):733–4.CrossRefGoogle Scholar
  48. 48.
    Francolla KA, Altman A, Sylvester FA. Hemophagocytic syndrome in an adolescent with Crohn disease receiving azathioprine and infliximab. J Pediatr Gastroenterol Nutr. 2008;47(2):193–5.CrossRefGoogle Scholar
  49. 49.
    Miquel T, Bonnet DP, Leport J, Longuet P, Bletry O, Leport C. Hemophagocytic syndrome in the course of Crohn’s disease: possible association with cytomegalovirus infection. Am J Gastroenterol. 2009;104(1):252.CrossRefGoogle Scholar
  50. 50.
    Côté-Daigneault J, Bernard EJ. Hepatosplenic lymphoma presenting initially as hemophagocytic syndrome in a 21-year-old man with Crohn’s disease: a case report and literature review. Can J Gastroenterol. 2011;25(8):417–8.CrossRefPubMedCentralGoogle Scholar
  51. 51.
    Ma C, Fedorak RN, Halloran BP. Recurrent fevers after infliximab therapy for ulcerative colitis. Gastroenterology. 2016;150(1):e1–2.  https://doi.org/10.1053/j.gastro.2015.04.048.CrossRefPubMedGoogle Scholar
  52. 52.
    Thompson G, Pepperell D, Lawrence I, McGettigan BD. Crohn’s disease complicated by Epstein-Barr virus-driven haemophagocytic lymphohistiocytosis successfully treated with rituximab. BMJ Case Rep. 2017;2017:pii:bcr2016218578. doi:  https://doi.org/10.1136/bcr-2016-218578.
  53. 53.
    Salado CT, Gallego AG, Carnerero EL, de la Cruz Ramírez D, Justiniano JMH, Galán JLM, et al. Hemophagocytic lymphohistiocytosis in Crohn’s disease associated with primary infection by Epstein-Barr virus. Inflamm Bowel Dis. 2011;17(11):E143–4.CrossRefGoogle Scholar
  54. 54.
    James DG, Stone CD, Wang HL, Stenson WF. Reactive hemophagocytic syndrome complicating the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2006;12(7):573–80.CrossRefGoogle Scholar
  55. 55.
    Reiner AP, Spivak JL. Hematophagic histiocytosis. A report of 23 new patients and a review of the literature. Medicine (Baltimore). 1988;67(6):369–88.CrossRefGoogle Scholar
  56. 56.
    Dao LN, He R. Hemophagocytic lymphohistiocytosis secondary to iatrogenic disseminated histoplasmosis. Blood. 2016;127(22):2775.CrossRefGoogle Scholar
  57. 57.
    Kim YC, Kim GM, Lee HS, et al. A case of hemophagocytic syndrome in an ulcerative colitis patient [in Korean]. Korean J Gastroenterol. 2010;56(1):45–8.CrossRefGoogle Scholar
  58. 58.
    •• Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152(8):1901–14.e3. Large pediatric study estimated the risk of HLH among thiopurine patients at 0.29 per 10,000 patient-years (95% CI, 0.09–0.68). Google Scholar
  59. 59.
    Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med. 2000;342(22):1627–32.CrossRefGoogle Scholar
  60. 60.
    Chande N, Wang Y, MacDonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2014;8:CD006618.  https://doi.org/10.1002/14651858.CD006618.pub3.CrossRefGoogle Scholar
  61. 61.
    Oren R, Arber N, Odes S, Moshkowitz M, Keter D, Pomeranz I, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology. 1996;110(5):1416–21.CrossRefGoogle Scholar
  62. 62.
    Maté-Jiménez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12(11):1227–33.CrossRefGoogle Scholar
  63. 63.
    •• Carbonnel F, Colombel JF, Filippi J, et al; European Crohn’s and Colitis Organisation and the Groupe d’Étude Thérapeutique des Affections Inflammatoires Digestives. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology. 2016;150(2):380–8.e4. Randomized, placebo-controlled trial showing that methotrexate was not effective in inducing remission in UC. Google Scholar
  64. 64.
    •• Herfarth HH, Barnes EL, Jackson S, et al; MERIT-UC study group. Methotrexate is not superior to placebo in maintaining remission in patients with ulcerative colitis: results from the MERIT-UC study [ECCO abstract P390]. J Crohns Colitis. 2018;12(suppl 1):S300–1. Randomized, placebo-controlled trial showing that methotrexate was not effective in maintaining remission in UC. Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Christopher M. Johnson
    • 1
  • Themistocles Dassopoulos
    • 2
  1. 1.Baylor Scott and White Medical CenterBaylor Scott and White HealthTempleUSA
  2. 2.Baylor University Medical CenterBaylor Scott and White HealthDallasUSA

Personalised recommendations